Eli Lilly and Company Acquires Disarm Therapeutics

Eli Lilly Acquires DICE Therapeutics

June 20, 2023

Biotechnology

Eli Lilly agreed to acquire DICE Therapeutics for $48 per share (approximately $2.4 billion) in an all-cash tender offer to bolster Lilly's immunology pipeline and leverage DICE's DELSCAPE small-molecule discovery platform and oral IL-17 inhibitor programs. The transaction, approved by both boards, is expected to close in Q3 2023 subject to customary conditions and antitrust clearance.

Merck Acquires Caraway Therapeutics

November 21, 2023

Biotechnology

Merck (MSD) will acquire Caraway Therapeutics, a Cambridge, Massachusetts–based preclinical biopharmaceutical company, for up to $610 million in potential consideration, including an undisclosed upfront payment and contingent milestone payments. The acquisition is intended to strengthen Merck’s research pipeline and capabilities in developing small-molecule treatments for genetically defined neurodegenerative and rare diseases.

Eli Lilly Acquires Sigilon Therapeutics

June 29, 2023

Biotechnology

Eli Lilly agreed to acquire Sigilon Therapeutics in a cash tender offer valuing the biotech at roughly $34.6 million up front plus contingent value rights that could increase total consideration to about $309.6 million. The acquisition brings Sigilon's encapsulated cell therapy platform (including SIG-002 for type 1 diabetes) into Lilly's diabetes and cell-therapy R&D efforts to accelerate development and potential commercialization.

Eli Lilly Acquires Dermira for $1.1 Billion

January 10, 2020

Biotechnology

Eli Lilly agreed to acquire Dermira, Inc. in an all-cash transaction valued at approximately $1.1 billion ($18.75 per share). The deal adds Dermira's Phase 3 IL-13 antibody candidate lebrikizumab and marketed dermatology product QBREXZA to Lilly's immunology and dermatology portfolio and is expected to close in Q1 2020.

Ariceum Therapeutics Acquires Theragnostics Ltd.

June 1, 2023

Biotechnology

Ariceum Therapeutics has acquired 100% of Theragnostics Ltd., a UK-based developer of radiopharmaceutical diagnostic and therapeutic products, for $2.5 million upfront plus up to $41.5 million of milestone payments. The deal gives Ariceum late preclinical/early clinical PARP inhibitor assets, US FDA‑approved NEPHROSCAN™ (partnered with GE Healthcare) and expanded US operations, strengthening its diagnostic and therapeutic radiopharmaceutical pipeline.

Insight Partners Acquires Armis for $1.1 Billion

January 6, 2020

Cybersecurity

Insight Partners completed the acquisition of Armis, the Palo Alto–headquartered enterprise IoT security platform, at a $1.1 billion valuation with participation from CapitalG. Armis will continue to operate independently under its co-founders while leveraging Insight’s ScaleUp resources to accelerate product and go-to-market expansion.